Inside This Issue of JACC  by unknown
I
Dnside This Issue of JACC
ECEMBER 2, 2008, VOLUME 52, NO. 23Page 1818
State-of-the-Art Paper
The High Burden of CVD in the Developing World
Cardiovascular disease (CVD) was the leading cause of death globally in 2005;more than 80% of the deaths occurred in low- and middle-income countries
(LMIC).WhileCVDmortality has decreasedby approximately three-quarters over the
past 3 decades in high-income countries, rates in many LMIC have increased. CVD is
now the leading cause of death in many LMIC, yet there is little access to proven
treatments. Joshi and colleagues outline, the barriers more widespread use of proven
medical therapies and suggest strategies that are tailored for the available resources in
LMIC. They propose that upgrading primary health care services is a central require-
ment for controlling the CVD epidemic facing the developing world. See page
1817. See figure.
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Antiplatelet Therapy
No Evidence of Decreased Clopidogrel Effectiveness Over 1 Year
Clopidogrel resistance has been described in 15% to 30% of patients with short-term therapy, but whether this changes with long-term therapy is unknown. Saw
and colleagues performed a serial analyses of clopidogrel and aspirin efficacy over 12
months. There was no change in maximal platelet adenosine diphosphate-stimulated
aggregation with light-transmittance aggregometry or VerifyNow clopidogrel platelet
inhibition from1 to12months. Similarly, therewas nodifference in aspirin’s effects on
platelet aggregation over 1 year.However, platelet expression of CD40L, CD62P, and
PAC-1 did increase over time. This pilot study showed no attenuation of clopidogrel’s
effects with long-term administration, but the increase in platelet activation receptors
merits further study. See page 1826. See figure.
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Cardiac Resynchronization
CRT Reduces Risk of Hospitalization
in Select NYHA Functional Class I and II Patients
This study evaluated theutility of cardiac resynchronization therapy (CRT) inNewYork Heart Association (NYHA) functional class II heart failure (HF) and
NYHA functional class I with previous HF symptoms who had a QRS120 ms and
a left ventricle (LV) ejection fraction40%.All subjects had aCRTdevice placed, but
were randomized to the device being turned ON or OFF. There was no difference in
the primary end point which included both symptoms and hospitalizations. However,
those with CRT-ON showed improved LV remodeling and had delayed times to first
HF hospitalization. This study shows that CRT can reduce the risk of hospitalization
and improve ventricular structure and function in patients with mild or resolved HF
symptoms. See pages 1834 and 1844. See figure.
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Cardiac Imaging
Noninvasive Imaging of MMP Activity
Matrix metalloproteinase (MMP) expression and activation contributes to thedegradation of fibrous caps and vulnerability to plaque rupture. Fujimoto and
colleagues studied a targeting radiotracer,MPI, that incorporates technetium-99minto
a compound that binds to MMP. The atherolsclerotic lesions in rabbits with experi-
mentally induced atherosclerosis, were clearly visible with micro–single photon emis-
sion computed tomography (SPECT)/computed tomography (CT) imaging. Further-
more, MPI uptake was significantly reduced after both dietary modification and
fluvastatin treatment and correlated with immunohistochemically-verified MMP-2
expression inplaques.This studydemonstrates the feasibility of noninvasive imagingof
MMP activity in atherosclerotic lesions. See page 1847. See figure.(continued on page A-40)
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Cell-Based Therapy
Combining FGF and Cardiac Stem Cells May Provide Synergistic Effect
Both cell-based therapy and therapeutic angiogenesis have been touted as potentialtreatments for ischemic heart disease (IHD), but the clinical results have been
disappointing. Takehara and colleagues describe a technique that embeds basic fibro-
blast growth factor (bFGF) into a gelatin which slowly degrades over 3 weeks and thus
provides sustained local delivery of bFGF. The gelatin is attached to the epicardial
surface with a polytetrafluoroethylene-reinforced pericardial sheet. This resulted in
enhanced myocardial perfusion and contractile function in a porcine model of IHD.
The effect of the bFGF patch on cell transplantation, was then studied and demon-
strated increased donor-cell engraftment and enhanced cardiomyocyte differentiation,
resulting in synergistically improved ventricular function.The sustained local release of
bFGF seems to create a favorablemillieu for engraftment and differentiation of cardiac
stem cells as well as neoangiogenesis. See pages 1858 and 1866.
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Mini-Focus:
Cell-Based Therapy
Myoendothelial Progenitor Cells
May Be Superior for Cardiac Cellular Transplantation
Okada and colleagues have recently identified a novel population ofmyoendothe-lial cells fromhuman skeletalmuscle that express bothmyogenic and endothelial
cell characteristics. The ability of these cells to improve post-myocardial infarction
cardiac function was tested in a mouse model and compared to transplantation of
regular myoblasts and endothelial progenitor cells. Intramyocardial injection of
myoendothelial cells produced greater improvements in left ventricular function and
more robust engraftment within the infarcted myocardium compared to injection of
myoblasts or endothelial cells. These findings suggest that myoendothelial cells repre-
sent a novel cell population from human skeletal muscle that may hold promise for
cardiac repair. See pages 1869 and 1881. See figure.
